Kornimate/medical-research-clean huggingface dataset:
a trial assessing the association between type of local anesthesia treatment and postoperative pain in patients in having undergone arrhythmia surgery

Conditions: Post-operative Pain

Summary: the goal of the proposed study is to investigate the relationship between two standard treatments, lidocaine or a mixture of lidocaine and bupivacaine, and 1) postoperative pain, and; 2) narcotic use following pacemaker or defibrillator insertion in subjects who undergo arrhythmia surgery at baylor heart and vascular institute while adjusting for pertinent clinical and/or demographic factors. no control group is necessary.

patients receiving a pacemaker or defibrillator are currently given bupivacaine, lidocaine, or a mixture of the two for local anesthetic treatment (in addition to general anesthesia). the choice of local anesthetic to be used during surgery is based primarily on the differences in time for the anesthetic to take effect and duration thereafter. lidocaine typically works in less than 1 minute and lasts approximately 45 minutes. bupivacaine works within 2 to 3 minutes and lasts 4 to 6 hours. lidocaine is often preferable due to its shorter time of effectiveness. however, its relatively short duration may translate into a higher use of narcotics for pain management during postoperative care - particularly within the first hour following emergence from general anesthesia. therefore it is conceivable that these patients would have higher levels of pain, higher cost of care related to cost of narcotics, and higher cost of caregiver time required to administer them.

Eligibility criteria:
inclusion criteria: * arrythmia patients receiving pacemaker or cardiac defibrillator devices at baylor heart and vascular institute. exclusion criteria: * receiving complicated procedures * replacement of parts, not inclusive of leads

Keywords: post-operative pain pain pacemaker defibrillator post-operative narcotic use local anesthesia
safety and tolerability of phenylbutyrate in inclusion body myositis

Conditions: Inclusion Body Myositis; Sporadic Inclusion Body Myositis

Summary: this is a pilot study (phase 1 clinical trial) to evaluate the safety and tolerability of phenylbutyrate in ibm. in this open label study, 10 patients with sporadic inclusion body myositis will be treated with phenylbutyrate (3 gm twice daily) for 3 months. there will be a run-in period, during which certain biomarkers will be measured at baseline and at the end of the run-in period in addition to final measurement at the end of the treatment period.


Eligibility criteria:
inclusion criteria: * fulfill enmc 2011 diagnostic criteria for ibm * age \> 18 years * women must be post-menopausal (no menses in \>12 months) or status post hysterectomy * able to give informed consent exclusion criteria: * presence of any one of the following medical conditions: chronic infection; chronic renal insufficiency; cancer other than skin cancer less than five years prior; multiple sclerosis or prior episode of central nervous system demyelination; or other chronic serious medical illnesses * presence of any of the following on routine blood screening: wbc\ 30 mg %; creatine \> 1.5 mg%; liver disease with serum albumin \< 3 g/dl * women who are pregnant or lactating * history of non-compliance with other therapies * coexistence of other muscular disease * drug or alcohol abuse within past three months * known bleeding disorder * known liver disease * known congestive heart failure * known hypernatremia * inability to give informed consent

Keywords: inclusion body myositis ibm pba phenylbutyrate
immunologic predisposition of hiv patients to develop methicillin-resistant staphylococcus aureus (mrsa) colonization and infection

Conditions: HIV Infections; Staphylococcal Infections

Summary: the purpose of this study is to investigate the role of t helper 17 cells (th17) in the pathogenesis of mrsa infections.


Eligibility criteria:
all participant inclusion criteria: * greater or equal to 18 years of age * willingness to undergo blood draw. skin biopsy will be requested, but is optional -and- hiv-positive and mrsa-negative group: * documented positive hiv test result * negative colonization swabs for s. aureus within 14 days of enrollment * no evidence of skin/soft tissue infection hiv-positive and mrsa-colonization group: * documented positive hiv test result * history of of colonization with mrsa w/in 14 days of study enrollment hiv-positive and mrsa infection group: * documented positive hiv test result * skin/soft tissue infection with a positive wound culture showing mrsa within 7 days of enrollment * mrsa infection is not associated with an intravenous catheter or other nosocomial procedure hiv negative groups: * same criteria used for the hiv-negative groups as listed above. * no history of hiv infection. * willing to undergo an hiv blood test, which must have a negative result. exclusion criteria: * women with positive urine pregnancy test within 7 days of study enrollment * women who are within 6 months of being postpartum or who are currently breastfeeding * subjects unable or unwilling to complete questionnaires and blood draw.

Keywords: hiv methicillin-resistant staphylococcus aureus (mrsa) hiv and staphylococcus aureus infection
radiofrequency therapy of the neck muscles for treating the post-dural puncture headache after cesarean delivery.

Conditions: Tecar Therapy Efficacy in the Treatment of PDPH

Summary: postdural puncture headache (pdph) is a frequent complication after neuraxial anaesthesia due to accidental puncture of the dura mater. after spinal anaesthesia, the rate of pdph may reach up to 28,7% of cases. pdph is more common in females, especially obstetric patients, young age and more after epidural than spinal anaesthesia because of needle type. pdph interferes with the patient's ability to resume activities, prolongs the hospital stay, and causes chronic headaches in up to 28% of cases. several treatment modalities were described for pdph. conservative treatment, an epidural blood patch, peripheral nerve blocks, such as sphenopalatine ganglion block (spgb) and more excellent occipital nerve block (gonb) using local anaesthetic block or through percutaneous radiofrequency ablation or direct injection of local anaesthetic and steroid directly into the neck muscles; were all proven effective in treating pdph. radiofrequency (rf) is a commonly used technique to treat different types of pain, headaches, and musculoskeletal abnormalities. the second-generation non-invasive rf modality was recently developed as tecar therapy (tecar: capacitive and resistive energy transfer). tecar therapy provided promising results in treating chronic pelvic and postpartum perineal pain. to our knowledge, tecar therapy efficacy in treating pdph has not been evaluated before. this study aims to assess the effectiveness of tecar therapy as a non-invasive technique for treating pdph. this study hypothesizes that tecar therapy could be an effective non-invasive technique for treating or reducing pdph.


Eligibility criteria:
inclusion criteria: * female patients aged over 18 years * asa physical status i or ii. * scheduled for elective cesarean delivery under spinal anaesthesia * who developed pdph with failed conservative treatment exclusion criteria: * patients with a history of long-standing diabetes. * peripheral vascular diseases * cervical spine disorders * receiving analgesics and anticonvulsant medication .
a psoriasis plaque test with leo 29102 cream and its combination products

Conditions: Psoriasis Vulgaris

Summary: the purpose of this trial is to evaluate the anti-psoriatic effect of leo 29102 cream and its combination with calcipotriol and betamethasone using a psoriasis plaque test method.


Eligibility criteria:
inclusion criteria: (in summary) * subjects having understood and signed an informed consent form * all skin types * subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or trunk. the lesions must have a total size suitable for application. the subjects should be asked if their lesions have been stable * subjects willing and able to follow all the study procedures and complete the whole study * subjects affiliated to social security system exclusion criteria: (in summary) * females who are pregnant, of child-bearing potential and who wish to become pregnant during the study, or who are breast feeding * subjects using biological therapies (marketed or not marketed) with a possible effect on psoriasis (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab) within 12 weeks prior to study drug administration * systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin d-analogues, retinoids, immunosuppressants) within the 4-week period prior to randomisation * subjects using one of the following topical drugs for the treatment of psoriasis within four (4) weeks prior to study drug administration: - potent or very potent (who group iii-iv) corticosteroids - puva or grenz ray therapy * subjects using one of the following topical drugs for the treatment of psoriasis within two (2) weeks prior to study drug administration: - who group i-ii corticosteroids - topical retinoids - vitamin d-analogues - topical immunomodulators (e.g. macrolides) - anthracen derivatives - tar - salicylic acid - uvb therapy * subjects with skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds within the plaque test areas
intensity modulated radiotherapy for breast cancer

Conditions: Breast Cancer

Summary: this study delivers radiation therapy to any residual breast tissue and the chest wall plus lymph node areas around the breast. these lymph node areas are under the arm, around the collar bone, and under the sternum (breastbone).

imrt treatment uses a computer-controlled x-ray (ct) to deliver radiation beams at several different angles and strengths to deliver precise doses to the regions at risk for recurrence of breast cancer while reducing or sparing the dose to critical structures (heart, lungs) and nearby normal tissue.

Eligibility criteria:
inclusion criteria: * female gender * age ≥ 18 years * invasive primary female breast cancer * pathologically proven regional nodal metastasis * status post mastectomy or partial mastectomy with an assessment of axillary nodes via sentinel lymph node biopsy and/or axillary lymph node dissection. * signed study specific consent form exclusion criteria: * distant metastasis * currently pregnant * psychiatric or addictive disorders that preclude informed consent * time from initial diagnosis to the start of radiation therapy \> one year * estimated life expectancy judged to be \< one year * prior radiation to the ipsilateral breast or chest wall * primary breast cancer is lymphoma or sarcoma * patients being treated with concurrent chemotherapy.

Keywords: imrt breast cancer with regional nodal metastasis
autoimmunity in retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of retinitis pigmentosa exclusion criteria: * cataract * extremely low erg wave amplitude (less than 8% of normal)
achieving understanding of the natural history of sickle cell trait (aunt)

Conditions: Sickle Cell Trait

Summary: the main purpose of this study is to create a longitudinal cohort of those with sickle cell trait (sct) to better understand the hematologic phenotype for those that carry hbs, assess for differences in those with varying quantities of hbs and assess for potential clinical complications of sct.


Eligibility criteria:
inclusion criteria: 1. are willing to voluntarily participate and sign the study consent 2. know/suspect they have sct and are willing to get tested to confirm/learn about their sct status 3. be willing and able to participate in the 2- year study plan. 4. adults ages 18-65 exclusion criteria: 1. unwilling to sign consent 2. known end-stage renal disease or dialysis 3. known scd (including sickle cell-beta thalassemia) 4. people who do not have sct
to study the role of retrograde intrarenal surgery in management of renal stones

Conditions: Retrograde Intrarenal Surgery In Management Of Renal Stones

Summary: role of retrograde intrarenal surgery in management of renal stones: single center experience

with the advancements in endourologic technology, in the last 30 years, renal stone treatment has dramatically changed, and minimally invasive treatments options, such as extracorporeal shock wave lithotripsy (swl), percutaneous nephrolithotomy (pcnl), mini-pcnl, retrograde intrarenal surgery (rirs) or laparoscopy, have replaced open surgery. although, minimally invasive treatment modalities have an excellent stone fragmentation rate, the clearance of stone fragments may not be immediate and can occur for any time after the intervention. the european association of urology (eau) guidelines, recommends pcnl for renal stones greater than 2 cm, and swl is suggested primarily for stones less than 1 cm in size. although swl, rirs and pcnl are all presented as treatment options for renal stones between, which application is a matter of preference. the treatment modality selection of renal stones usually depends on stone-related factors (location, size, and composition), clinical factors (patient's comorbidities, patient's compliance, solitary kidney, and abnormal anatomy), and technical factors (equipment available for treatment, success rates, possible complications, invasiveness, the need for anesthetics, hospitalization times, and costs). pcnl can achieve better results but is more invasive, is associated with greater morbidity and complications, and may be reserved for selected circumstances. stone clearance following kidney stone treatment is not well defined. for lower pole stones, sener and colleagues compared rirs with swl and reported a stone-free rate of 52.3% with patients treated using rirs one week after treatment. however after three months, the stone-free rate improved to 100%. ureteroscopic lithotripsy has been the most widely applied treatment for urinary tract stones, with high success and low complication rates. the holmium laser has facilitated the disintegration of stones and increased the effectiveness of ureteroscopic lithotripsy. improvements in the new generation of flexible ureteroscopes have made retrograde endoscopic ureteroscopy and laser lithotripsy for renal calculi more popular. the overall success rates of retrograde intrarenal surgery have been reported as 75% to 95% for intrarenal stones \> 2 cm after the first or second treatment, whereas the major and minor complication rates vary from 1.5% to 12%, which are less frequent than rates in pcnl procedures.

Eligibility criteria:
inclusion criteria: * all patients with renal stones were eligible for the procedure. patients with difficult pcnl exclusion criteria: * uncorrected coagulopathy distal obstruction active urinary tract infection ureteropelvic junction obstruction congenital renal anomalies staghorn stones

Keywords: renal pelvic stone semi-rigid urs flexible urs treatment
children's hospital academic medical organization (chamo) mychart study

Conditions: Diabetes Mellitus, Type 1

Summary: evolving technology and clinical innovation have led to dramatic changes in the management of type 1 diabetes (t1d). these changes have led to a need to collect a growing number of details from families during their visits. as a result, much of the physician-patient visit is spent transferring information instead of focusing on diabetes care, contributing to increased time pressures in clinic and unmet needs for patients. in response to this reality, the investigators have developed a tool that allows families to input their diabetes-related information into their physicians' electronic health record (ehr) documentation tool before their clinic visit, using a questionnaire administered via cheo's secure patient portal (mychart®). the investigators will evaluate the impact of an integrated electronic patient questionnaire, on quality of care (patient-reported), diabetes control and clinic efficiency. the investigators hope that our study will determine whether having families input clinical data prior to a visit is an effective strategy to improve the quality of diabetes care. the investigators believe that the findings will be of interest to all those studying the value of incorporating patient-entered data both within diabetes care and beyond.


Eligibility criteria:
inclusion criteria: * diagnosis of t1d * age \<11 years at enrollment exclusion criteria: * patients ≥ 11 years of age at enrollment * patients who are not fluent enough in english to complete all study related procedures * patients unable or unwilling to provide consent and/or assent * patients followed in eating disorder clinic or child and youth protection clinic (there are mychart activation restrictions for individuals followed in these clinics)
the effectiveness of oral corticosteroids in the treatment of lumbar stenosis

Conditions: Spinal Stenosis of Lumbar Region

Summary: the aim of this study is to evaluate the effectiveness of the use of systemic corticosteroids administered orally in narrow lumbar canal syndrome.

60 patients are being randomized, plank by randomization, the patient and the examiner will be blinded. will be placed in opaque brown envelopes in order to maintain the secrecy of allocation. included patients aged between 50 and 75 years of both sexes participate in the work to accept and sign the informed consent the patient will be screened in advance after the acceptance of it will be an anthropometric assessment, with assessment of height, weight and presence of associated comorbidities. after clinical evaluation they headed for the initial evaluation, after this evaluation, patients are randomized and and delivered to the patient the medication with corticosteroids or placebo for an unrelated medical research. it is also given a bottle of paracetamol 750 mg and a sheet dated, in which the patient is instructed to register the day this sheet and number of capsules taken, which is also an evaluation factor. evaluation vas sf 36 roland morris questionnaire test 6-minute walk likert scale elegibility criteria clinical diagnosis: low back pain and at least two of the following complaints in lower limbs: pain, weakness, burning or numbness that worsens with walking and improves with the cessation of walking. radiological diagnosis: presence of lumbar canal stenosis with an area less than 100mm2 hamanishi based on criteria measured at lumbar spine mri in the follow-up from l1 to s1.

Eligibility criteria:
inclusion criteria: * low back pain and at least two of the following complaints in lower limbs: pain, weakness, burning or numbness that worsens with walking and improves with the cessation of walking. exclusion criteria: * decompensated diabetes mellitus. * systemic hypertension and decompensated heart * systemic disease affecting the lower limbs * neuromuscular disease * use of steroids in the past 3 months. * patients with previous surgery of the thoracic or lumbar spine. * cognitive disorder that interferes with the ability to understand or interpret the questionnaires * spondylolisthesis except degenerative * degenerative scoliosis with cobb angle of 10 °

Keywords: lumbar stenosis systemic corticosteroids outcome security
asian multicenter prospective study in her2 positive early breast cancer for detecting mrd by ctdna;harmony study

Conditions: HER2-positive Breast Cancer

Summary: this study will assess minimal residual disease (mrd) in her2-positive early breast cancer patients in asian countries. the purpose is to evaluate the relation between the detection rate of mrd and recurrence.

this study will evaluate the relation between the detection rate of minimal residual disease(mrd) and recurrence in her2-positive early breast cancer patients in asian countries. blood will be regularly collected to check the presence of ctdna in her2-positive breast cancer patients who have scheduled for neoadjuvant chemotherapy followed by surgery. prognostic data is also collected on the same patients. mrd is a small number of cancer cells left in the body during or after treatment. these cells have the potential to cause recurrence in cancer patients. mrd detection can help identify patients at increased risk of disease recurrence and guide treatment decisions. however, limited data are available on when ctdna analysis should be done in the course of treatment, and what is the appropriate analysis method. this study will contribute to determining whether mrd detection using ctdna is useful to predict the recurrence of her2-positive early breast cancer patients. if this can be proven, it is expected that detection of mrd can use as a biomarker to assist in the de-/escalation of treatment strategies, therefore allowing to avoid overtreatment in patients at low risk, and to add more intensive treatment in patients at high risk. moreover, studying with asian countries, the results will become the basic data for approval of liquid biopsy.

Eligibility criteria:
inclusion criteria: 1. age of 20 years or older at the date of registration. 2. histological diagnosis of her2-positive invasive breast carcinoma. 3. patients scheduled for neoadjuvant chemotherapy followed by surgery. 4. clinical stage iia-iiic. 5. known hormone receptor status. 6. signed informed consent. exclusion criteria: 1. any other malignancy within 5 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the esophagus, stomach, colon, or cervix. 2. bilateral synchronous breast cancer. 3. history of breast cancer. 4. pregnancy at registration.
detection of microplastics and nanoplastics in neurosurgery patients (dt-mini)

Conditions: Carotid Artery Stenosis; Glioma; Intracranial Aneurysm; Intracranial Hemorrhages; Brain Tumor

Summary: plastic particles are a ubiquitous pollutant in the living environment and food chain, so far, plenty of studies have reported the internal exposure of microplastics and nanoplastics in human tissues and enclosed body fluids. neurosurgery is the only department that can open the skull. in addition to blood and cerebrospinal fluid, there are brain tissue and tumors in the presence of lesions. whether any of these microplastics and nanoplastics are present remains a mystery. this prospective observational study will harvest biological samples of neurosurgery patients. the objective of this research is to be able to detect microplastics and nanoplastics on blood and operation samples of neurosurgery patients.


Eligibility criteria:
inclusion criteria: * age 18-80 years * any type of neurosurgery exclusion criteria: ·refusal of the patient to participate

Keywords: microplastics nanoplastics intracranial aneurysm brain tumor carotid artery stenosis
early clinical experience with anidulafungin in patients with liver disease in the united kingdom

Conditions: Candidiasis

Summary: the purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large liver unit in the united kingdom.

all subjects that have been treated with anidulafungin according to its licence during the period of july 2009 and september 2010 will be included.

Eligibility criteria:
inclusion criteria: * subjects who have been prescribed anidulafungin between 1st july 2009 and 30th september 2010. patients admitted to specialist liver unit wards and the liver intensive therapy unit during this period exclusion criteria: * patients who participated in any interventional clinical trial during this episode of sepsis. patients who received anidulafungin for infection prophylaxis

Keywords: ecalta eraxis candida candidemia systemic candidiasis icu intensive care unit critical care unit